Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma

about

Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma

Item

http://www.wikidata.org/entity/Q58767936

description

article

@en

im August 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Spanish Lymphoma Group (GELTAM ...... diffuse large B-cell lymphoma

@en

Spanish Lymphoma Group (GELTAM ...... diffuse large B-cell lymphoma

@nl

type

Item

label

Spanish Lymphoma Group (GELTAM ...... diffuse large B-cell lymphoma

@en

Spanish Lymphoma Group (GELTAM ...... diffuse large B-cell lymphoma

@nl

prefLabel

Spanish Lymphoma Group (GELTAM ...... diffuse large B-cell lymphoma

@en

Spanish Lymphoma Group (GELTAM ...... diffuse large B-cell lymphoma

@nl

P1476

Spanish Lymphoma Group (GELTAM ...... diffuse large B-cell lymphoma

@en

P2093

Alejandro Martín

http://www.w3.org/2001/XMLSchema#string

Andrés López-Hernández

http://www.w3.org/2001/XMLSchema#string

Carlos Montalbán

http://www.w3.org/2001/XMLSchema#string

Carlos Panizo

http://www.w3.org/2001/XMLSchema#string

Eva González-Barca

http://www.w3.org/2001/XMLSchema#string

Guillermo Rodríguez

http://www.w3.org/2001/XMLSchema#string

Mónica Coronado

http://www.w3.org/2001/XMLSchema#string

Spanish Lymphoma Group (GELTAMO)

http://www.w3.org/2001/XMLSchema#string

P2860

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.

Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.

P304

32383-32399

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.25892

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Santiago Montes-Moreno

Juan-Manuel Sancho

P577

2018-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30190794

http://www.w3.org/2001/XMLSchema#string

P932

6122355

http://www.w3.org/2001/XMLSchema#string